title: Policosanol prevents bone loss in ovariectomized rats.
abstract: Osteoporosis is characterized by reduced bone mass, abnormal bone architecture and increased fracture risk. Ovariectomy impairs bone mass and metabolism in rats and ovariectomized rats are considered as a suitable model of postmenopausal osteoporosis. Mevalonate is required for producing lipoids that are important in osteoclast activity and thus drugs affecting mevalonate production can prevent bone loss in rodents. Policosanol is a cholesterol-lowering drug isolated from sugar cane wax that inhibits cholesterol biosynthesis through an indirect regulation of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase activity. The purpose of this study was to determine whether policosanol could prevent bone loss in the bones of ovariectomized rats by comparing its effects with those induced by estradiol. Sprague Dawley female rats were randomly distributed in four groups: a sham-operated group treated with Tween/H2O vehicle and three groups of ovariectomized rats treated with 17beta-estradiol (30 microg/kg/day) or policosanol (50 and 200 mg/kg/day), respectively, for 3 months. At treatment completion the rats were sacrificed, their bones removed and variables of bone resorption and formation were investigated by histomorphometry. Ovariectomy increased trabecular separation but diminished the number and thickness of trabecules. Estradiol and policosanol prevented these effects compared with ovariectomized controls. Both treatments also prevented an increase in the number of osteoclasts and their surface area induced by ovariectomy. Estradiol, but not policosanol, significantly prevented an increase of osteoblast surface area compared with ovariectomized controls. In conclusion, policosanol prevented bone loss and decreased bone resorption in ovariectomized rats, suggesting that it should be potentially useful in preventing bone loss in postmenopausal women.
authors.affiliation: Center of Natural Products of the National Center for Scientific Research, Havana City, Cuba. clinica@enet.cu
authors.forename: M
authors.initials: M
authors.lastname: Noa
authors.forename: R
authors.initials: R
authors.lastname: Más
authors.forename: S
authors.initials: S
authors.lastname: Mendoza
authors.forename: R
authors.initials: R
authors.lastname: Gámez
authors.forename: N
authors.initials: N
authors.lastname: Mendoza
authors.forename: J
authors.initials: J
authors.lastname: González
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004958:Estradiol / Q000008:administration & dosage / Q000493:pharmacokinetics; D005233:Fatty Alcohols / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007441:Intubation, Gastrointestinal; D010010:Osteoclasts / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy / Q000517:prevention & control*; D010052:Ovariectomy; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005233:Fatty Alcohols; D010936:Plant Extracts; C080710:policosanol; D004958:Estradiol